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Abstract
Background: Conventional randomized placebo-controlled study design assumes the absence of drug*placebo
interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might
be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare
conventionally estimated and interaction model-estimated drug effects (secondary).
Methods: We used a hybrid of balanced placebo and randomized placebo-controlled designs. Four hundred eighty
healthy volunteers were randomized to three groups. The first received hydroxyzine (25 mg) described as hydroxyzine
or placebo, the second received placebo described as hydroxyzine or placebo, and the third received hydroxyzine and
placebo described as unknown; each in a randomized crossover design. Seven participants failed to crossover. Group
assignment was concealed from participants and study coordinators. Coordinators were blinded to group and
intervention assignment. Participants and coordinators were deceived as to study objectives. Main outcomes were
mean area-under-the-curve of drowsiness (therapeutic outcome) and mouth-dryness (adverse outcome), self-reported
on 100 mm visual analog scale over 7 h. Drug, placebo, placebo + interaction, and total effects were estimated using
analysis of covariance by comparing received hydroxyzine/told placebo to received placebo/told placebo, received
placebo/told hydroxyzine to received placebo/told placebo, received hydroxyzine/told hydroxyzine to received
hydroxyzine/told placebo, and received hydroxyzine/told hydroxyzine to received placebo/told placebo, respectively.
Drug effect was also conventionally estimated in the third group.
Results: Mean (SD) age was 31.4 (6.6) years, 65% were males. There was significant difference between placebo +
interaction effect and placebo effect for both drowsiness and mouth-dryness with a mean difference (95% confidence
interval) of 35.1 (5.6 to 64.6) and 23.8 (2.4 to 45.2) mm*hr, respectively. Total effect was larger than the sum of drug and
placebo effects for drowsiness (139.7 (109.8 to 169.6) vs. 99.1 (68.2 to 130.0) mm*hr) and mouth-dryness (63.6 (41.1 to
86.1) vs. 34.7 (11.1 to 58.4) mm*hr). Conventionally estimated drug effect was larger than interaction model-estimated
drug effect for drowsiness (69.2 (45.5 to 92.8) vs. (58.3 (31.6 to 85.0) mm*hr) and mouth-dryness (19.9 (5.3 to 34.5) vs. 9.5
(−9.2 to 28.1) mm*hr).
Conclusions: There is significant and important drug*placebo interaction effect that may bias conventionally
estimated drug effect.
(Continued on next page)
* Correspondence: Muhammad@kfshrc.edu.sa
1Department of Clinical Studies and Empirical Ethics, King Faisal Specialist Hospital
and Research Center, P O Box # 3354 (MBC 03), Riyadh 11211, Saudi Arabia
2Alfaisal University College of Medicine, Riyadh, Saudi Arabia
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hammami et al. BMC Medical Research Methodology  (2016) 16:166 
DOI 10.1186/s12874-016-0269-1
(Continued from previous page)
Trial registration: ClinicalTrial.gov identifier: NCT01501591 (registered December 25, 2011).
Keywords: Balanced placebo design, Randomized placebo-controlled trials, Biased drug effect size, Drug placebo
interaction, Effect modification
Background
The drug effect of a medication is conventionally best
estimated by comparing the placebo and medication
arms of randomized placebo-controlled trials (RPCT).
The comparison can be made on an additive scale or
multiplicative scale, i.e., calculating the difference or
ratio of the results in the two arms, respectively.
Changes observed in the placebo arm, referred to as “pla-
cebo” response, results from the meaning response
(placebo effect) [1] and non-specific passive changes [2, 3],
such as regression to the mean and Hawthorne effect.
Interventions are described as “additive” if their
effects do not interact and as “non-additive” if their
effects reciprocally modify each other. The interaction
or effect modification could be positive or negative
and could be seen on one or both of the additive and
multiplicative scales.
Participants in the medication arm of an RPCT are ex-
posed to both the drug effect and the placebo effect,
whereas participants in the placebo arm are exposed to
the placebo effect only. Regardless of whether the addi-
tive or multiplicative scale is used, the common inter-
pretation of RPCTs is based on the assumption that the
drug effect and the placebo effect are “additive”, i.e.,
there is no drug*placebo interaction or effect modifica-
tion [3]. Thus to estimate the drug effect, changes ob-
served in the placebo arm are simply “subtracted” from
those observed in the medication arm. If a drug*placebo
interaction effect does exist, it would be restricted to the
medication arm, the difference between the two arms
would be more or less than the drug effect, and conven-
tionally estimated drug effect would be biased [4, 5].
Balanced placebo design, where subjects receiving a
medication or placebo are either told that they are re-
ceiving the medication or placebo [6], can model total
medication effect into drug, placebo, and drug*placebo
interaction effects [7]. However, because of the (mis) in-
formation provided to participants, the design raises
substantial ethical concerns and may raise suspicion
among participants [8]. We have previously used a
modification of the balanced placebo design, namely,
balanced placebo crossover design to study the drug*pla-
cebo interaction effect [9]. The crossover version and
other novel designs were later advocated to overcome
the shortcomings of the balanced placebo design [8].
Nevertheless, even the balanced placebo crossover de-
sign has ethical constraints. Further, it does not allow
direct comparison of interaction model-estimated drug
effect and conventionally estimated drug effect.
In the current study, we used a hybrid of balanced
placebo crossover design and RPCT design to estimate
the drug*placebo interaction effect (primary aim) and
compare interaction model-estimated and conventionally
estimated drug effects (secondary aim). We recruited
healthy volunteers and used hydroxyzine, a medication
with known safety profile, to minimize ethical concerns.
Primary outcomes were a therapeutic effect (drowsiness)
and an adverse effect (mouth-dryness) of hydroxyzine.
To verify that study procedures are effective in inducing
and measuring the placebo effect, our study design in-
cluded two control outcomes, nausea as a positive con-
trol (participants were told that hydroxyzine causes
nausea, but it doesn’t), and itchiness as a negative con-
trol (participants were told that hydroxyzine doesn’t
cause itchiness, and it doesn’t).
Methods
Design
The design was a hybrid of crossover-balanced placebo
and RPCT designs. In effect, participants were random-
ized to three groups or three randomized crossover
arms. The first group received hydroxyzine twice, de-
scribed as hydroxyzine or placebo, the second group
received placebo twice, described as hydroxyzine or
placebo, and the third group received hydroxyzine and
placebo described as unknown (Fig. 1).
Participants
Healthy volunteers were recruited via advertisement
throughout the King Faisal Specialist Hospital and Re-
search Center (KFSH&RC). Main eligibility criteria were
an age of 18–50 years (based on safety reasons) and abil-
ity to use visual analog scales (VAS) reproducibly. The
study was conducted at KFSH&RC from November
2012 through October 2015 between 8:00–8:30 am to
3:00–3:30 pm. It followed ethical guidelines on decep-
tion use in research [10, 11] and was approved by
KFSH&RC Research Ethics Committee. Participants gave
a written “consent”, being told that the study compares
25 mg hydroxyzine to placebo to determine how much
of the hydroxyzine-related symptoms aren’t caused by
hydroxyzine, and that they have a 50/50 chance of re-
ceiving hydroxyzine or placebo. They were compensated
based on the Wage-Payment model [12] and were
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contacted post-study for debriefing on the actual study pur-
pose and design and for delayed full consenting. Headache
was reported by seven participants (three received hydroxy-
zine, four received placebo), back pain by one, fever by two,
and left-sided chest warmness by one (all received hydroxy-
zine). All symptoms were mild and resolved spontaneously.
Procedures and interventions
Participants were reminded to abstain from smoking,
caffeine, and alcohol for 16 h, from food for 10 h, and
from water for 1 h, and to have ≥7 h of good sleep be-
fore each study period. On study day, baseline data were
obtained and a standardized breakfast was served,
A C
B D
Fig. 1 Models of Positive and Negative Drug*Placebo Interaction Effect in Balanced Placebo and Conventional Randomized Placebo-Controlled
Designs. a and b depict balanced placebo design. c and d depict conventional randomized placebo-controlled design. A positive drug*placebo
interaction model is presented in a and c. A negative drug*placebo interaction model is presented in b and d. Hydroxyzine is used as the model
drug. a & b Under the balanced placebo design, ooutcome measures in received placebo/told placebo represent none-specific passive changes
(baseline); in received placebo/told hydroxyzine, placebo effect and baseline; in received hydroxyzine/told placebo, drug effect and baseline; and
in received hydroxyzine/told hydroxyzine, drug, placebo, drug*placebo interaction effects, and baseline. The total effect of ingesting a hydroxyzine
capsule is the difference between received hydroxyzine/told hydroxyzine and received placebo/told placebo and consists of drug, placebo, and
drug*placebo interaction effects. The interaction model-estimated drug effect is the difference between received hydroxyzine/told placebo and
received placebo/told placebo and consists of the drug effect only. The model predicts two different estimates of the placebo effect: placebo
effect-1, the difference between received hydroxyzine/told hydroxyzine and received hydroxyzine/told placebo, which consists of the placebo
and the drug*placebo interaction effects; and placebo effect-2, the difference between received placebo/told hydroxyzine and received placebo/
told placebo, which consists of the placebo effect only. Placebo effect-1 is larger than placebo effect-2 if there is positive interaction effect (a)
and smaller if there is negative interaction effect (b). c & d Under the conventional randomized placebo-controlled design, outcome measures in
received hydroxyzine/told unknown represent the drug effect, part of the placebo effect (because of participants’ knowledge that there is 50%
chance of receiving hydroxyzine) and consequently part of the drug*placebo interaction effect, and baseline; and in received placebo/told
unknown, part of the placebo effect (because of participants’ knowledge that there is 50% chance of hydroxyzine) and baseline. Conventionally
estimated drug effect is the difference between received hydroxyzine/told unknown and received placebo/told unknown and consists of the
drug effect and part of the interaction effect. It is larger than the interaction model-estimated drug effect if there is positive interaction effect
(compare a and c) and smaller if there is negative interaction effect (compare b and d)
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followed 15–30 min later by intervention administration.
Participants remained ambulatory or seated upright for
4 h, were allowed to drink ≤120 ml of water hourly, and
were served standardized lunch at 4 h.
Intervention administration (by MMH) involved indi-
vidually informing participants that hydroxyzine (but
not placebo) may cause drowsiness, mouth-dryness, and
nausea, but not itchiness; asking them to carefully read
and sign another “consent” statement that included
study purpose, expected symptoms, and current assign-
ment; and watching them swallow one hydroxyzine or
placebo capsule dispensed from containers with clear,
purposely-displayed labels. Group-1 received two 25 mg
hydroxyzine capsules (described as hydroxyzine or pla-
cebo) 72 h apart, group-2, received two placebo capsules
(described as hydroxyzine or placebo) 72 h apart, and
group-3, one hydroxyzine capsule and one placebo cap-
sule (described as unknown with 50/50 chance of being
hydroxyzine or placebo) 72 h apart.
Hydroxyzine, clinically used for sedation and treatment
of pruritus and nausea, was chosen for its safety profile
and subjective effects. Sedation usually starts within 1 h
and persists for 6 h, plasma half-life is around 20 h, and
mouth-dryness is rather common. [13] A 25 mg dose was
selected to avoid a ceiling effect that would reduce the
ability to detect a positive drug*placebo interaction effect.
Hydroxyzine capsules were manufactured from commer-
cially available 25 mg hydroxyzine hydrochloride tablets
and contained similar amount of lactose as the color- and
shape-matched placebo capsules. Hydroxyzine concentra-
tion was blindly measured by high performance liquid
chromatography assay [14].
Outcome measures
Co-primary outcome measures were area-under-the-curve
(AUC) of drowsiness and mouth-dryness levels assessed
on 100 mm horizontal VAS at baseline and 0.5, 1.0, 1.5,
2.0, 2.5, 3.0, 4.0, 5.0, 6.0, and 7.0 h after administering the
intervention. Levels of nausea and itchiness were assessed
in the same way to be used as positive and negative con-
trol outcomes, respectively, of the placebo effect. As such,
we did not consider them primary outcomes to be regis-
tered at clinicaltrial.gov. However, they were stated in the
original proposal. Each VAS was anchored by word de-
scriptors at each end, and scores were determined in mm.
Secondary outcome measures were mean number of times
drowsiness and mouth-dryness were reported on a binary
scale at the same time points. At each time point, data col-
lection sheets were handed to participants and then
collected and checked for completeness by coordinators.
Randomization
Randomization schedule was generated (by MMH) using
a program available on-line (www.randomization.com).
We block-randomized (block size = 6) 480 slots to six as-
signments: hydroxyzine described as hydroxyzine
followed by hydroxyzine described as placebo, hydroxy-
zine described as placebo followed by hydroxyzine
described as hydroxyzine (group-1), placebo described as
placebo followed by placebo described as hydroxyzine,
placebo described as hydroxyzine followed by placebo
described as placebo (group-2), blinded hydroxyzine
followed by blinded placebo, and blinded placebo
followed by blinded hydroxyzine (group-3). Group as-
signment was concealed from participants and study
coordinators.
Blinding and deception
Study coordinators were blinded to group and interven-
tion assignments and were deceived as to study
objectives. Participants were deceived as to study objec-
tives and partially deceived (group-1 and group-2) or
blinded (group-3) to individual assignment. To enhance
blinding/deception and verify compliance, blood samples
for hydroxyzine concentration were drawn at 3 h, and
participants were requested not to reveal their assign-
ments to the coordinators. To assess blinding, the coor-
dinators were asked to guess the intervention
(hydroxyzine or placebo) at 1 h. To assess deception,
participants were asked during post-study debriefing
whether they believed their intervention assignment or
guessed actual study objectives and design.
Interaction model
The interaction model assumes that outcome measures
in participants who receive placebo and are told that it
is inert (received placebo/told placebo), represent non-
specific passive changes. These measures are used as ref-
erence (baseline) since they do not include a drug effect
or a placebo effect. In participants who receive placebo
but are told that it is an active drug (received placebo/
told drug), there would be a placebo effect but no drug
effect. In participants who receive an active drug and are
told that it is active drug (received drug/told drug), there
would be a drug effect, placebo effect, and drug*placebo
interaction effect. In participants who receive an active
drug but are told that it is inert (received drug/told pla-
cebo), there would be a drug effect but no placebo effect;
the placebo effect would be “subtracted.” In RPCT, par-
ticipants typically know that they have 50% chance of re-
ceiving an active drug and 50% chance of receiving a
placebo. If they do receive an active drug (received drug/
told unknown), there would be a full drug effect, part of
the placebo effect, and consequently, part of the drug*-
placebo interaction effect. If they do receive a placebo
(received placebo/told unknown), there would be part of
the placebo effect and no drug effect. Based on the
model, the following estimations can be made:
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1) Total effect is the difference between received drug/
told drug and received placebo/told placebo; it
consists of the drug effect, placebo effect, and
drug*placebo interaction effect.
2) Interaction model-estimated drug effect is the
difference between received drug/told placebo and
received placebo/told placebo; it consists of the drug
effect only.
3) Drug + interaction effect is the difference between
received drug/told drug and received placebo/told
drug; it consists of the interaction model-estimated
drug effect and the drug*placebo interaction effect.
4) Conventionally estimated drug effect is the
difference between received drug/told unknown and
received placebo/told unknown; it consists of the
drug effect and part of the interaction effect.
5) Placebo effect plus interaction effect (here called
placebo effect-1) is the difference between received
drug/told drug and received drug/told placebo; it
consists of the placebo effect and the drug*placebo
interaction effect.
6) Placebo effect only (here called placebo effect-2) is
the difference between received placebo/told drug
and received placebo/told placebo; it consists of the
placebo effect only.
The model predicts that if there is a positive drug*placebo
interaction effect, placebo effect-1 would be larger than pla-
cebo effect-2, total effect would be larger than the sum of
the interaction model-estimated drug effect and placebo
effect-2, and conventionally estimated drug effect would be
larger than interaction model-estimated drug effect. The
opposites would be expected with negative interaction.
Thus, the model appropriately addresses the primary and
secondary aims of the study, i.e., whether placebo effect-1 is
different from placebo effect-2 and whether interaction
model-estimated drug effect is different from convention-
ally estimated drug effect. The model also predicts that
there would be drug, placebo, and drug*placebo interaction
effects on drowsiness and mouth-dryness, only placebo ef-
fect on nausea, and no drug or placebo effects on itchiness.
The positive and negative interaction models are presented
in Fig. 1 using the study drug, hydroxyzine, as example.
Sample size
The study was designed to have adequate power to com-
pare placebo + interaction (placebo-1) and placebo only
(placebo-2) effects in group-1 and group-2, respectively
(primary aim). It was planned to recruit 160 subjects in
each group, based on an expected standardized mean
difference of 0.33 [9], type I error of 0.05, type II error
of 0.2, and 10% dropout rate. An additional 160 subjects
(group-3) were included to measure conventionally esti-
mated drug effect (secondary aim).
Statistical analysis
Outcome measures were evaluated by analysis of covari-
ance. For within-group analysis (to estimate placebo
effect-1, placebo effect-2, and conventionally estimated
drug effects), statistical model included intercept, base-
line value, period, intervention, group, and subject-
nested within group. The last two terms were omitted
for between-group analysis (to estimate drug + inter-
action, total, and interaction model-estimated drug ef-
fects). Comparison of estimated effect sizes was
performed by the z test; the combined standard error
was calculated as the square root of sum of squares of
the separate standard errors [15]. Predefined primary
and secondary outcomes were differences between
placebo effect-1 and placebo effect -2 and between con-
ventionally estimated and model-estimated drug effects,
respectively. Non-parametric tests were used for second-
ary analysis. Analyses were performed (by MMH) with
IBM SPSS Statistics version 21 software. Two-tailed
p-values and 95% confidence intervals are reported.
Analyses were not adjusted for multiple comparisons.
Results
We screened 554 volunteers and found 34 ineligible (13
due to medical history, 11 to laboratory results, 10 to
failing the VAS screening test). Forty of the 520 eligible
volunteers did not show up; 480 were randomized.
Seven participants lost to crossover for personal reasons
and were excluded from analysis (Fig. 2). Study coordi-
nators correctly guessed participants’ assignment (hy-
droxyzine vs. placebo) 52% of the time. We were able to
contact 266 (56%) out of the 473 participants for post-
study debriefing, all gave full informed consent. Out of
the 266, 264 (99%) were unable to guess the actual study
objectives or design, and 129 were assigned to group-1
or group-2. Out of the 129, 118 (91%) believed what they
were told at the time of administering the intervention
(two did not, nine had doubt), and 102 (80%) believed it
at all times (13 did not, 14 had doubt), indicating suc-
cessfulness of blinding and deception. Plasma hydroxy-
zine concentrations confirmed compliance of all
participants.
Overall mean (SD) age was 31.4 (6.6) years, and 309/
473 (65%) were males. Table 1 summarizes participants’
characteristics per assignment. Baseline differences of
outcome measures among the six assignments were not
significant (p = 0.10–0.74). Figure 3 depicts unadjusted
mean (SE) VAS scores of drowsiness and mouth-dryness
(A and B) and unadjusted mean number of times the
two symptoms were reported (C and D).
Differences between period 1 and period 2 were sig-
nificant for baseline drowsiness (mean difference
1.5 mm, p < 0.001), mouth-dryness (4.4 mm, p < 0.001),
nausea (0.8 mm, p = 0.002), but not itchiness (0.3 mm, p
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= 0.18). Further, in analysis of covariance, there was sig-
nificant period effect on mean AUC of drowsiness
(25.3 mm*hr, p < 0.001), mouth-dryness (16.2 mm*hr, p
< 0.001), nausea (6.7 mm*hr, p = 0.003), and itchiness
(3.4 mm*hr, p = 0.02); and on mean number of times
drowsiness (p = 0.01), mouth-dryness (p = 0.003), nausea
(p = 0.006), and itchiness (p = 0.007) were reported. There-
fore, all estimates were adjusted for the period effect.
There was also significant overall intervention effect
on mean AUC of drowsiness, mouth-dryness, and nau-
sea (p < 0.001) but not itchiness (p = 0.93) and on mean
number of times drowsiness, mouth-dryness, and nausea
were reported (p < 0.001).
Drug effect
Adjusted mean (95% confidence interval) AUC of model-
estimated and conventionally-estimated drug effects were,
respectively, 58.3 mm*hr (31.6 to 85.0, p < 0.001) and
69.2 mm*hr (45.5 to 92.8, p < 0.001) on drowsiness,
9.5 mm*hr (−9.2 to 28.1, p = 0.32) and 19.9 mm*hr (5.3 to
34.5, p = 0.008) on mouth-dryness, 0.5 mm*hr (−6.4 to
7.4, p = 0.89) and 3.0 mm*hr (−1.9 to 8.0, p = 0.23), on
nausea (Fig. 4 (a to c)), and 2.5 mm*hr (−6.0 to 11.0, p =
0.56) and -0.7 mm*hr (−4.5 to 3.2, p = 0.73) on itchiness.
The results indicate that the RPCT overestimates drug
effect by about 19, 109, and 500% for drowsiness, mouth-
dryness, and nausea, respectively (Fig. 3 (e & f) and Fig. 4
(d to f)). Interestingly, outcome measures in received
hydroxyzine/told unknown were intermediate between
those in received hydroxyzine/told hydroxyzine and those
in received hydroxyzine/told placebo (Figs. 3 and 4).
Using non-parametric tests, unadjusted conventionally
estimated drug effect was significant for AUC of drowsi-
ness (p < 0.001), mouth-dryness (p = 0.01), but not nau-
sea (p = 0.60), whereas, model-estimated drug effect was
significant for AUC of drowsiness (p < 0.001) but not
mouth-dryness (p = 0.21) or nausea (p = 0.73).
Placebo effect
Adjusted mean AUC of placebo effect-1 and placebo
effect-2 were, respectively, 75.9 mm*hr (50.8 to 101.0, p
< 0.001) and 40.8 mm*hr (24.9 to 56.7, p < 0.001) for
drowsiness, 49.1 mm*hr (33.3 to 64.8, p < 0.001) and
25.3 mm*hr (10.5 to 40.0, p = 0.001) for mouth-dryness,
19.9 mm*hr (10.1 to 29.7, p < 0.001) and 7.5 mm*hr (0.1
to 14.9, p = 0.047) for nausea (Fig. 4 (a to c)), and
0.5 mm*hr (−6.7 to 7.7, p = 0.89) and 1.6 mm*hr (−2.0 to
5.3), p = 0.39) for itchiness. Further, adjusted placebo
effect-1 and placebo effect-2 on binary scale (mean num-
ber of reports per 100 persons) were, respectively, 182
Fig. 2 Flow of Participants through the Study
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(121 to 243, p < 0.001) and 143 (89 to 197, p < 0.001) for
drowsiness, 158 (103 to 213, p < 0.001) and 147 (86 to
209, p < 0.001) for mouth-dryness, and 76 (36 to 116, p
< 0.001) and 36 (7 to 65, p = 0.01) for nausea.
Using non-parametric tests, placebo effect-1 was
significant for AUC of drowsiness (p < 0.001), mouth-
dryness (p < 0.001), and nausea (p < 0.001), whereas,
placebo effect-2 was significant for AUC of drowsiness
(p < 0.001), mouth-dryness (p < 0.001), but not nausea (p
= 0.08). There was significant correlation of placebo
effect-1 on mouth-dryness and drowsiness (rho = 0.52, p
< 0.001) and on mouth-dryness and nausea (rho = 0.36,
p < 0.001). There was also significant correlation of pla-
cebo effect-2 on mouth-dryness and drowsiness (rho =
0.64, p < 0.001) and on mouth-dryness and nausea (rho
= 0.62, p < 0.001).
Time course of drug and placebo effects
As shown in Fig. 3 (e and f), placebo effect-2 started earl-
ier than drug effect and was rather flat, drug effect peaked
around 2–3 h, and interaction model-estimated drug
effect started to decline earlier than conventionally-
estimated drug effect.
Drug*placebo interaction effect
Mean difference between placebo effect-1 (placebo and
interaction effects) and placebo effect-2 (placebo effect
alone) was 35.1 mm*hr (5.6 to 64.6, p = 0.02) for
drowsiness, 23.8 mm*hr (2.4 to 45.2, p = 0.03) for
mouth-dryness, and 12.4 mm*hr (0.2 to 24.6, p = 0.047)
for nausea. Further, drug + interaction effect was larger
than interaction model-estimated drug effect with a
mean difference of 42.6 mm*hr (1.3 to 84.0, p = 0.04) for
drowsiness, 28.7 mm*hr (−1.5 to 58.9, p = 0.06) for
mouth-dryness, and 14.1 mm*hr (−0.4 to 28.5, p = 0.06)
for nausea. Furthermore, the total effect was larger than
the sum of the interaction model-estimated drug effect
and placebo effect-2 with a mean difference of
40.6 mm*hr (−2.3 to 83.5, p = 0.06) for drowsiness,
28.8 mm*hr (−3.7 to 61.4, p = 0.08) for mouth-dryness,
and 12.8 mm*hr (−2.4 to 27.9, p = 0.09) for nausea.
The total effect on drowsiness, mouth-dryness, and nau-
sea was 139.7 mm*hr (109.8 to 169.6), 63.6 mm*hr (41.1 to
Table 1 Baseline characteristics of study participants
Characteristics Hydroxyzine Group Placebo Group Blinded Hydroxyzine/Placebo Group
Age, mean (SD), yr. 31.5 (6.4) 30.8 (6.1) 31.8 (7.2)
Sex, no. (%)
Female 50 (32) 56 (35) 58 (36)
Male 106 (68) 102 (65) 101 (64)
Completed education, no. (%)
High school 36 (23) 38 (24) 30 (19)
College 85 (55) 72 (46) 88 (55)
University 35 (22) 48 (30) 41 (26)
Occupational status, no. (%)
Professional, technical, managerial 32 (22) 45 (29) 37 (24)
Clerical, sales 1 (1) 0 (0) 2 (1)
Service 107 (72) 99 (63) 101 (66)
Agricultural, fishery, related 0 (0) 1 (1) 2 (1)
House wife 0 (0) 1 (1) 2 (1)
Student 5 (3) 6 (4) 7 (5)













Drowsiness level, mean (SD), mma 4.5 (6.0) 6.3 (10.1) 4.7 (6.6) 5.1 (8.5) 4.9 (7.3) 4.6 (8.0)
Mouth-dryness level, mean (SD), mm a 5.9 (9.5) 8.5 (15.5) 6.2 (10.2) 6.1 (11.5) 5.5 (8.8) 5.7 (11.6)
Nausea level, mean (SD), mm a 2.8 (4.4) 3.0 (5.8) 2.9 (4.9) 3.5 (7.4) 2.3 (5.2) 3.0 (6.4)
Itchiness level, mean (SD), mm a 2.8 (3.8) 2.6 (4.3) 2.8 (4.5) 3.1 (5.3) 2.7 (4.5) 2.7 (4.4)
Hydroxyzine group (group-1, n = 156): received 25 mg hydroxyzine twice and told its hydroxyzine on one time and placebo on the other, in a randomized
crossover design. Placebo group (group-2, n = 158): received placebo twice and told its placebo on one time and 25 mg hydroxyzine on the other, in a
randomized crossover design. Blinded hydroxyzine/placebo group (group-3, n = 159): received 25 mg hydroxyzine and placebo in a randomized single-blinded
crossover design. Numbers may not sum up to group totals because of missing data and percentages may not add to 100% because of rounding
a Measured on 100 mm visual analog scale
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86.1), and 20.8 mm*hr (9.4 to 32.1), respectively (Fig. 4 (d
to f)). Therefore, it can be calculated that the drug*placebo
interaction effect accounted for about 25, 37, and 60% of
the total effect on drowsiness, mouth-dryness, and nausea.
Discussion
We used a hybrid of balanced placebo and RPCT de-
signs to determine the drug*placebo interaction effect
(predefined primary objective), and 2) compare model-
estimated drug effect obtained from the balanced pla-
cebo design to conventionally estimated drug effect
obtained from the RPCT design (predefined secondary
objective). We studied hydroxyzine pharmaceutical and
placebo effects on healthy volunteers and measured
drowsiness (therapeutic outcome), mouth-dryness (ad-
verse outcome), nausea (positive control outcome for
the placebo effect), and itchiness (negative control
outcome for the placebo and drug effects). We found
statistically significant and clinically important positive
interaction effect on drowsiness, mouth-dryness, and
nausea and that conventionally estimated drug effect is
larger than model-estimated drug effect.
The specific placebo effect (meaning response) is often
difficult to separate from the more general placebo re-
sponse that may involve regression to the mean, natural
course, Hawthorne effect, and the general effect of
patient-physician relation (such as sympathy) [1–3, 16].
The placebo effect is not restricted to inert sub-
stances; it contributes importantly to total medication
effect [7, 9, 17] and is lost with a false belief of re-
ceiving an inert substance [18].
Drug and placebo effects, just like any other effects, may
interact. Since the medication arm, but not the placebo
arm, of RPCT would have the interaction effect, the
A C E
B D F
Fig. 3 Time Course of Self-Reported Drowsiness and Mouth-dryness According to Intervention or Type of Effect. a to d mean unadjusted scores
on continuous scale (a and b) and binary scale (c and d) per intervention. Squares indicate receiving 25 mg hydroxyzine, described as hydroxyzine
(closed square with continuous line), as placebo (open square with interrupted line), or as unknown (closed square with dotted line). Circles indicate
receiving placebo, described as placebo (closed circle with continuous line), as hydroxyzine (open circle with interrupted line), or as unknown (closed
circle with dotted line). e and f mean adjusted scores per type of effect. Closed diamonds indicate total effect; closed squares interaction model-
estimated drug effect, open squares conventionally estimated drug effect, and closed circle placebo effect. T-bars indicate standard errors
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assumption that the difference between the two arms rep-
resents the drug effect [4, 16] may be incorrect. In this
study, we found that the placebo effect was significantly
larger when measured using hydroxyzine (described as hy-
droxyzine or placebo) than when measured using placebo
(described as hydroxyzine or placebo). The first measure-
ment includes both the placebo and interaction effects,
whereas the second includes only the placebo effect. Fur-
ther, the combination of placebo and drug effects was
smaller than the total effect. Furthermore, conventionally
estimated drug effect, which includes the drug effect plus
part of the interaction effect, was larger than model-
estimated drug effect. In a previous study, we showed that
there may be negative drug*placebo interaction effect of
caffeine on energy and sleepiness [9]. More recently,
others showed significant negative drug*placebo inter-
action effect of lidocaine on experimental pain [7].
Both size and direction of interaction effects depend
on whether causal contrasts are estimated on additive
(difference) or multiplicative (ratio) scale. Although both
the current and previous studies used the additive scale,
the current study is the first to show positive interaction
effect. Negative interaction may be related to ceiling of
the effect, whereas, positive interaction may be related








Fig. 4 Mean Area-Under-the-Curve According to Intervention or Type of Effect. a to c adjusted mean area-under-the-curve after receiving 25 mg
hydroxyzine (black bars), described as hydroxyzine (H/H), as placebo (H/P), or as unknown (H/U); or placebo (grey bars), described as hydroxyzine
(P/H), as placebo (P/P), or as unknown (P/U). d to f adjusted interaction model-estimated drug effect (black bars), drug*placebo interaction effect
(dotted bars), placebo effect (white bars), conventionally estimated drug effect (vertical strips bars), and total effect (horizontal strips bars). T-bars
indicate standard errors. * p <0.05, ** p <0.001
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The study makes two other interesting observations. We
found drug*placebo interaction effect on mouth-dryness
and nausea despite the absence of significant model-
estimated drug effect, which suggests that interaction of
effectors may not be restricted to be on the same outcome;
drug effect on drowsiness appears to have interacted with
the placebo effect on mouth-dryness and nausea (cross-out-
come interaction). We also found that response to hydroxy-
zine given as unknown (with 50% possibility of being
hydroxyzine) was intermediate between the response to
open hydroxyzine and hidden hydroxyzine, suggesting that
the relationship between the degree of subject’s certainty
about receiving an intervention and the placebo effect is
rather linear. This is in agreement with a recent review of
indirect evidence [8] but in contrast to what was previously
hypothesized [19].
Limitations
Intervention’s administration by an undeceived investi-
gator may have reduced the placebo effect and conse-
quently the interaction effect. However, post-study
debriefing revealed that 91% of participants believed
what they were told at the time of intervention and 80%
at all times. On the other hand, the balanced placebo de-
sign is prone to experimental subordination bias that
might exaggerate the placebo response [16]. Since it was
emphasized to participants that hydroxyzine effects do
not occur all the time or in all persons, participants
knew that coordinators were blinded to their assign-
ments, and there was no patient-physician relationship
or even further contact between the investigator who ad-
ministered the intervention and the participants, such
bias would be small. Further, biases related to the esti-
mation of the placebo effect would not be expected to
influence the primary conclusion of the study, whether
or not an interaction effect exists. Another limitation of
the study design is the learning effect, which is present
in all crossover designs. Thus, deception and blinding
would not be expected to be completely successful.
However, the results of our post-study debriefing indi-
cate that this limitation is rather minor and not likely to
have a major effect on our conclusions. Finally, our
study was performed on healthy volunteers using a small
dose of hydroxyzine and it is not clear how much of the
observed interaction effect would be present in RPCT
on patients. Nevertheless, current interpretation of
RPCT results is based on a model that assumes that
there is no interaction between drug and placebo effects.
Finding one example where such assumption is falsified
is enough to question the model.
Implications
The possibility that there may be drug*placebo inter-
action effect has important implications. For example, a
negative interaction effect may explain the trivial antide-
pressants effect observed in most clinical trials [4, 9]. Al-
ternatively, the observed trivial effect may be entirely
due to cross-outcome interaction between the placebo
effect on depression and side effects of antidepressants,
with no antidepressant drug effect. Further, when com-
paring drug effects across RPCTs, it may be important
to control for the interaction effect, since the placebo ef-
fect and hence the interaction effect may not be the
same across trials. Furthermore, differences between the
two arms of active-control trials may be related in part
to differential interaction effect rather than purely to dif-
ferential drug effect. Moreover, unblinding in RPCTs,
would bias estimated drug effect not only because of dif-
ferential placebo effect in the two arms but also because
of different interaction effect. In addition, because of the
potential cross-outcome interaction effect, active placebos
may be more accurate than inert placebos in determining
drug effects; partial placebo and partial cross-outcome
interaction effects in the active placebo arm would cancel
out the partial placebo and partial interaction effects in
the drug arm. Finally, estimating the placebo effect by the
open-hidden active drug design may be biased since the
difference between the two arms would include an inter-
action effect.
Conclusions
In this large hybrid design study, using hydroxyzine as a
model drug, we found that there is a significant and im-
portant positive drug*placebo interaction effect on addi-
tive scale and that conventional measurement of drug
effect size by randomized placebo-controlled trials may
be biased.
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